Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with metastatic NSCLC and a mutation causing MET exon 14 skipping, confirmed using an FDA-approved test.
LAMPGEN ANALYSIS
Why it matters
FDA converted the existing biomarker-defined accelerated approval to traditional approval.
What research teams should watch
Preserve the original decision date in historical reporting and keep the MET exon-skipping result distinct from other MET alterations.
PRIMARY RECORDS